Comparison of Comorbid Associations and Ocular Complications in Herpes Simplex and Zoster Keratitis.

A retrospective chart review examined adult patients with herpes simplex (HSV) and zoster (HZO) keratitis at a single institution. Patients who suffered a poor outcome (defined as visually significant corneal scarring, neurotrophic keratitis, secondary glaucoma, or requiring corneal surgery) were identified and each outcome type was analyzed in relation to age, sex, diabetes mellitus, immunosuppression, and a prior history of ≥2 ocular procedures.Advanced age, diabetes mellitus, and a prior history of ≥2 ocular procedures may be risk factors for poor outcomes in HSV, but not HZO, keratitis. In HSV, older age and DM were specifically associated with visually significant corneal scarring, while older age and male sex were associated with secondary glaucoma. Future prospective studies are warranted to determine the ideal management (including prophylaxis) in patients with these characteristics.

Ischemic optic neuropathy after Descemet-stripping automated endothelial keratoplasty.

An 82-year-old woman presented with a failed Descemet-stripping automated endothelial keratoplasty (DSAEK) in her right eye performed a month earlier. The patient underwent uneventful repeat DSAEK. Six days after the procedure, the patient was found to have an afferent pupillary defect and optic nerve swelling in her right eye on fundoscopy and optical coherence tomography. A comprehensive workup, including bilateral temporal artery biopsies and magnetic resonance imaging, for vasculitic etiologies was negative. A diagnosis of nonarteritic anterior ischemic optic neuropathy (NAION) was made. Although NAION has been reported after various ocular surgeries, to the authors' knowledge, this is the first reported case of NAION after uneventful corneal transplantation. Therefore, NAION should be considered a rare complication of corneal transplantation surgery. Meticulous preoperative and postoperative evaluation, including an attentive pupillary and dilated fundus examination, are essential in assessing a patient's risk factors for this condition and monitoring for its occurrence in the perioperative period.

Refractive outcomes of phacoemulsification after pars plana vitrectomy using traditional and new intraocular lens calculation formulas.

PURPOSE: To evaluate refractive outcomes of cataract surgery in previously vitrectomized eyes and compare the accuracy of intraocular lens (IOL) calculation formulas in this population. SETTING: Stony Brook University Hospital, Stony Brook, New York, USA. DESIGN: Retrospective case series. METHODS: All electronic medical records of patients who had phacoemulsification from 2013 to 2017 were reviewed. Patients who had previously had pars plana vitrectomy in the same eye were selected. Patients with a history of refractive surgery, silicone oil in the eye, or other factors preventing accurate IOL power calculation were excluded. RESULTS: The mean postoperative spherical equivalent was -0.16 diopter (D) ± 0.81 (SD) (n = 61). The mean prediction errors were 0.30 ± 0.82 D, -0.09 ± 0.76 D, 0.23 ± 0.76 D, 0.25 ± 0.81 D, 0.04 ± 0.85 D, 0.30 ± 0.82 D, 0.33 ± 0.79 D, and 0.45 ± 0.80 D with the Holladay 1, Wang/Koch (WKA) adjusted Holladay 1 (n = 14), Holladay 2 (n = 48), SRK/T, WKA SRK/T (n = 14), Hill-Radial Basis Function (n = 50), and Ladas formulas, respectively. The formula with the highest percentage of predictions within ±0.50 D of the postoperative outcome was the Holladay 2 (60.42%). Statistically significant differences between the predicted and actual refractive outcomes were found with all formulas (P < .05) except the WKA Holladay and WKA SRK/T. Intraclass correlation showed low repeatability (<0.50) for all formulas. CONCLUSIONS: Refractive outcomes after cataract extraction in vitrectomized patients can be variable and more hyperopic than the predicted outcomes using traditional and newer IOL calculation methods. Thus, predicting refractive outcomes in this population is challenging, and patients should be counseled accordingly.

Influence of Early Descemet Stripping Endothelial Keratoplasty on Visual Outcomes in Pseudophakic Corneal Edema.

PURPOSE: Longstanding corneal edema can lead to anterior stromal scarring that may limit visual acuity following Descemet stripping endothelial keratoplasty (DSEK). The ideal time to perform DSEK to prevent permanent changes is unclear. Our aim is to determine whether earlier DSEK is associated with improved visual outcomes. DESIGN: Cohort study. METHODS: Setting: Institutional. STUDY POPULATION: Total of 120 eyes of patients who underwent DSEK for corneal edema following cataract surgery (CE); 87% of eyes had a diagnosis of Fuchs dystrophy. INTERVENTION: Post-DSEK visual acuity was compared in patients who underwent DSEK ≤6 months vs >6 months after CE. Linear and logistic regression were performed to assess the relationships between DSEK timing and best spectacle-corrected visual acuity (BSCVA) while accounting for baseline preoperative patient characteristics. MAIN OUTCOME MEASURES: Postoperative best-corrected visual acuity 6 months after DSEK (POM6 BSCVA). RESULTS: Median CE-to-DSEK time was 8.62 (interquartile range [IQR] 12.28) months (n = 120). Overall median preoperative VA and POM6 BSCVA were 0.54 (IQR 0.68) and 0.24 (IQR 0.16), respectively. Median POM6 BSCVA was better in patients with CE-to-DSEK time ≤6 months (median 0.18, IQR 0.19) vs >6 months (median 0.30, IQR 0.21) (P = .014). A significant relationship was found between CE-to-DSEK time and POM6 BSCVA (coefficient = 0.002, P = .033), accounting for preoperative vision and pachymetry. Patients who underwent DSEK ≤6 months after CE were more likely to achieve POM6 BSCVA better than 20/40 (odds ratio = 3.73 P = .035). CONCLUSION: Performing earlier DSEK for pseudophakic corneal edema appears to be associated with improved vision. Further prospective study is warranted to determine the optimal time to perform DSEK in patients with pseudophakic corneal edema.

Management of aniridia and iris defects: an update on iris prosthesis options.

PURPOSE OF REVIEW: This review examines the advantages and limitations of the various iris prostheses as treatment for aniridia. RECENT FINDINGS: Multiple prosthetic iris devices have been developed for implantation in eyes with aniridia. However, none is currently approved for use in the USA. SUMMARY: Aniridia can be congenital or traumatic in etiology and can lead to glare and other visual disturbances. Treatment options include colored contact lenses, corneal tattooing, and corneal stromal implants, although these carry significant risks of infection and corneal scarring. Prosthetic iris devices can often simultaneously treat aphakia or cataract as well as aniridia, and various models are currently available around the world from Morcher GMBH (Kapuzinerweg 12, 70374 Stuttgart, Germany), Ophtec USA Inc. (6421 Congress Ave Suite 12, Boca Raton, FL 33487, USA) and HumanOptics (Erlangen, Germany). Surgical planning and technique are important in optimizing the safety of these devices. The CustomFlex iris prosthesis from HumanOptics can be implanted within the capsular bag or ciliary sulcus with scleral fixation and offers excellent cosmetic outcomes. At present, the HumanOptics prosthetic iris is being investigated in a multicenter clinical trial.